Rituximab is effective in the treatment of refractory immune thrombocytopenic purpura associated with chronic lymphocytic leukemia [6]

Southern Medical Journal

Volumn 98, Issue 12, 2005, Pages 1227-1228

  Oo, Thein H ^a  

^a ST ELIZABETH'S MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

DANAZOL; IMMUNOGLOBULIN; MEPREDNISONE; PREDNISONE; RITUXIMAB;

AGED; CASE REPORT; CHRONIC LYMPHATIC LEUKEMIA; DISEASE ASSOCIATION; DRUG EFFICACY; ECCHYMOSIS; FEMALE; HUMAN; IDIOPATHIC THROMBOCYTOPENIC PURPURA; LABORATORY TEST; LETTER; RECTUM HEMORRHAGE; SPLENECTOMY; THROMBOCYTE COUNT; TREATMENT OUTCOME;

AGED; ANTIBODIES, MONOCLONAL; FEMALE; HUMANS; IMMUNOLOGIC FACTORS; LEUKEMIA, LYMPHOCYTIC, CHRONIC; PURPURA, THROMBOCYTOPENIC, IDIOPATHIC;

EID: 30344488413     PISSN: 00384348     EISSN: None     Source Type: Journal    
DOI: 10.1097/01.smj.0000190101.56301.a2     Document Type: Letter

References (5)

1. Kazkaz H, Isenberg D. Anti B cell therapy (rituximab) in the treatment of autoimmune diseases. Curr Opin Pharmacol 2004;4:398-402.
2. Zaja F, Vianelli N, Sperotto A, et al. Anti-CD20 therapy for chronic lymphocytic leukemia-associated autoimmune diseases. Leukemia & Lymphoma 2003;44:1951-1955.
3. Hegde UP, Wilson WH, White T, et al. Rituximab treatment of refractory fludarabine-associated immune thrombocytopenia in chronic lymphocytic leukemia. Blood 2002;100:2260-2262.
4. Jacoub J, Mchlayeh W, Tabbara I, et al. The use of anti-CD20 chimeric monoclonal antibody, rituximab, in adult patients with treatment refractory immune thrombocytopenia. [Abstract #3050] Blood 2004;104:74b.
5. Cabrera JR, Penalver FJ, Milan I, et al. Mabthera (Rituximab) in the treatment of 92 patients with refractory immune thrombocytopenic purpura. [Abstract #2074] Blood 2004;104:571a.